Cholinergic Regulation of the Suprachiasmatic Nucleus Circadian Rhythm Via a Muscarinic Mechanism at Night
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Severe Organophosphate Poisoning with Delayed Cholinergic Crisis, Intermediate Syndrome and Organophosphate Induced Delayed Polyneuropathy on Succession
Organophosphate Poisoning… Aklilu A 203 CASE REPORT SEVERE ORGANOPHOSPHATE POISONING WITH DELAYED CHOLINERGIC CRISIS, INTERMEDIATE SYNDROME AND ORGANOPHOSPHATE INDUCED DELAYED POLYNEUROPATHY ON SUCCESSION Aklilu Azazh ABSTRACT Organophosphate compounds are the organic derivatives of Phosphorous containing acids and their effect on neuromuscular junction and Autonomic Synapses is clinically important. After exposure these agents cause acute and sub acute manifestations depending on the type and severity of the agents like Acute Cholinergic Manifestations, Intermediate Syndrome with Nicotinic features and Delayed Central Nervous System Complications. The patient reported here had severe Organophosphate Poisoning with various rare complications on a succession. This is the first report of Organophosphates Poisoning complicated by Intermediate Syndrome and Organophosphate Induced Delayed Polyneuropathy in Ethiopia and it is reported to increase awareness of health care workers on these rare complications of a common problem. INTRODUCTION phosphorylated by the Phosphate end of Organophosphates; then the net result is Organophosphate compounds are the organic accumulation of excessive Acetyl Chlorine with derivatives of Phosphorous containing acids and resultant effect on Muscarinic, Nicotinic and their effect on Neuromuscular Junction and central nervous system (Figure 2). Autonomic synapses is clinically important. In the Neuromuscular Junction Acetylcholine is released Following classical OP poisoning, three well when a nerve impulse reaches -
The Superior Colliculus–Pretectum Mediates the Direct Effects of Light on Sleep
Proc. Natl. Acad. Sci. USA Vol. 95, pp. 8957–8962, July 1998 Neurobiology The superior colliculus–pretectum mediates the direct effects of light on sleep ANN M. MILLER*, WILLIAM H. OBERMEYER†,MARY BEHAN‡, AND RUTH M. BENCA†§ *Neuroscience Training Program and †Department of Psychiatry, University of Wisconsin–Madison, 6001 Research Park Boulevard, Madison, WI 53719; and ‡Department of Comparative Biosciences, University of Wisconsin–Madison, Room 3466, Veterinary Medicine Building, 2015 Linden Drive West, Madison, WI 53706 Communicated by James M. Sprague, The University of Pennsylvania School of Medicine, Philadelphia, PA, May 27, 1998 (received for review August 26, 1997) ABSTRACT Light and dark have immediate effects on greater REM sleep expression occurring in light rather than sleep and wakefulness in mammals, but the neural mecha- dark periods (8, 9). nisms underlying these effects are poorly understood. Lesions Another behavioral response of nocturnal rodents to of the visual cortex or the superior colliculus–pretectal area changes in lighting conditions consists of increased amounts of were performed in albino rats to determine retinorecipient non-REM (NREM) sleep and total sleep after lights-on and areas that mediate the effects of light on behavior, including increased wakefulness following lights-off (4). None of the rapid eye movement sleep triggering by lights-off and redis- light-induced behaviors (i.e., REM sleep, NREM sleep, or tribution of non-rapid eye movement sleep in short light–dark waking responses to lighting changes) appears to be under cycles. Acute responses to changes in light conditions were primary circadian control: the behaviors are not eliminated by virtually eliminated by superior colliculus-pretectal area le- destruction of the suprachiasmatic nucleus (24) and can be sions but not by visual cortex lesions. -
Protocol for a Randomised Controlled Trial: Efficacy of Donepezil Against
BMJ Open: first published as 10.1136/bmjopen-2013-003533 on 25 September 2013. Downloaded from Open Access Protocol Protocol for a randomised controlled trial: efficacy of donepezil against psychosis in Parkinson’s disease (EDAP) Hideyuki Sawada, Tomoko Oeda To cite: Sawada H, Oeda T. ABSTRACT ARTICLE SUMMARY Protocol for a randomised Introduction: Psychosis, including hallucinations and controlled trial: efficacy of delusions, is one of the important non-motor problems donepezil against psychosis Strengths and limitations of this study in patients with Parkinson’s disease (PD) and is in Parkinson’s disease ▪ In previous randomised controlled trials for (EDAP). BMJ Open 2013;3: possibly associated with cholinergic neuronal psychosis the efficacy was investigated in patients e003533. doi:10.1136/ degeneration. The EDAP (Efficacy of Donepezil against who presented with psychosis and the primary bmjopen-2013-003533 Psychosis in PD) study will evaluate the efficacy of endpoint was improvement of psychotic symp- donepezil, a brain acetylcholine esterase inhibitor, for toms. By comparison, this study is designed to prevention of psychosis in PD. ▸ Prepublication history for evaluate the prophylactic effect in patients this paper is available online. Methods and analysis: Psychosis is assessed every without current psychosis. Because psychosis To view these files please 4 weeks using the Parkinson Psychosis Questionnaire may be overlooked and underestimated it is visit the journal online (PPQ) and patients with PD whose PPQ-B score assessed using a questionnaire, Parkinson (http://dx.doi.org/10.1136/ (hallucinations) and PPQ-C score (delusions) have Psychosis Questionnaire (PPQ) every 4 weeks. bmjopen-2013-003533). been zero for 8 weeks before enrolment are ▪ The strength of this study is its prospective randomised to two arms: patients receiving donepezil design using the preset definition of psychosis Received 3 July 2013 hydrochloride or patients receiving placebo. -
The Role of Serotonin in Memory: Interactions with Neurotransmitters and Downstream Signaling
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Bushehr University of Medical Sciences Repository Exp Brain Res (2014) 232:723–738 DOI 10.1007/s00221-013-3818-4 REVIEW The role of serotonin in memory: interactions with neurotransmitters and downstream signaling Mohammad Seyedabadi · Gohar Fakhfouri · Vahid Ramezani · Shahram Ejtemaei Mehr · Reza Rahimian Received: 28 April 2013 / Accepted: 20 December 2013 / Published online: 16 January 2014 © Springer-Verlag Berlin Heidelberg 2014 Abstract Serotonin, or 5-hydroxytryptamine (5-HT), is there has been an alteration in the density of serotonergic found to be involved in many physiological or pathophysi- receptors in aging and Alzheimer’s disease, and serotonin ological processes including cognitive function. Seven dis- modulators are found to alter the process of amyloidogen- tinct receptors (5-HT1–7), each with several subpopulations, esis and exert cognitive-enhancing properties. Here, we dis- have been identified for serotonin, which are different in cuss the serotonin-induced modulation of various systems terms of localization and downstream signaling. Because involved in mnesic function including cholinergic, dopa- of the development of selective agonists and antagonists minergic, GABAergic, glutamatergic transmissions as well for these receptors as well as transgenic animal models as amyloidogenesis and intracellular pathways. of cognitive disorders, our understanding of the role of serotonergic transmission in learning and memory has Keywords Serotonin · Memory · Signaling pathways improved in recent years. A large body of evidence indi- cates the interplay between serotonergic transmission and Abbreviations other neurotransmitters including acetylcholine, dopamine, 2PSDT Two-platform spatial discrimination task γ-aminobutyric acid (GABA) and glutamate, in the neu- 3xTg-AD Triple-transgenic mouse model of Alzheimer’s robiological control of learning and memory. -
Drug Class Review Ophthalmic Cholinergic Agonists
Drug Class Review Ophthalmic Cholinergic Agonists 52:40.20 Miotics Acetylcholine (Miochol-E) Carbachol (Isopto Carbachol; Miostat) Pilocarpine (Isopto Carpine; Pilopine HS) Final Report November 2015 Review prepared by: Melissa Archer, PharmD, Clinical Pharmacist Carin Steinvoort, PharmD, Clinical Pharmacist Gary Oderda, PharmD, MPH, Professor University of Utah College of Pharmacy Copyright © 2015 by University of Utah College of Pharmacy Salt Lake City, Utah. All rights reserved. Table of Contents Executive Summary ......................................................................................................................... 3 Introduction .................................................................................................................................... 4 Table 1. Glaucoma Therapies ................................................................................................. 5 Table 2. Summary of Agents .................................................................................................. 6 Disease Overview ........................................................................................................................ 8 Table 3. Summary of Current Glaucoma Clinical Practice Guidelines ................................... 9 Pharmacology ............................................................................................................................... 10 Methods ....................................................................................................................................... -
Molecular and Cellular Networks in the Suprachiasmatic Nuclei
International Journal of Molecular Sciences Review Molecular and Cellular Networks in The Suprachiasmatic Nuclei Lama El Cheikh Hussein, Patrice Mollard and Xavier Bonnefont * Institut de Génomique Fonctionnelle (IGF), University Montpellier, CNRS, INSERM, 34094 Montpellier, France; [email protected] (L.E.C.H.); [email protected] (P.M.) * Correspondence: [email protected]; Tel.: +33-4-3435-9306 Received: 1 April 2019; Accepted: 23 April 2019; Published: 25 April 2019 Abstract: Why do we experience the ailments of jetlag when we travel across time zones? Why is working night-shifts so detrimental to our health? In other words, why can’t we readily choose and stick to non-24 h rhythms? Actually, our daily behavior and physiology do not simply result from the passive reaction of our organism to the external cycle of days and nights. Instead, an internal clock drives the variations in our bodily functions with a period close to 24 h, which is supposed to enhance fitness to regular and predictable changes of our natural environment. This so-called circadian clock relies on a molecular mechanism that generates rhythmicity in virtually all of our cells. However, the robustness of the circadian clock and its resilience to phase shifts emerge from the interaction between cell-autonomous oscillators within the suprachiasmatic nuclei (SCN) of the hypothalamus. Thus, managing jetlag and other circadian disorders will undoubtedly require extensive knowledge of the functional organization of SCN cell networks. Here, we review the molecular and cellular principles of circadian timekeeping, and their integration in the multi-cellular complexity of the SCN. -
Suprachiasmatic Modulation of Noradrenaline Release in the Ventrolateral Preoptic Nucleus
6412 • The Journal of Neuroscience, June 13, 2007 • 27(24):6412–6416 Brief Communications Suprachiasmatic Modulation of Noradrenaline Release in the Ventrolateral Preoptic Nucleus Benoıˆt Saint-Mleux,1 Laurence Bayer,1 Emmanuel Eggermann,1 Barbara E. Jones,2 Michel Mu¨hlethaler,1 and Mauro Serafin1 1De´partement de Neurosciences Fondamentales, Centre Me´dical Universitaire, 1211 Gene`ve 4, Switzerland, and 2Department of Neurology and Neurosurgery, McGill University, Montreal Neurological Institute, Montreal, Quebec, Canada H3A 2B4 As the major brain circadian pacemaker, the suprachiasmatic nucleus (SCN) is known to influence the timing of sleep and waking. We thus investigated here the effect of SCN stimulation on neurons of the ventrolateral preoptic nucleus (VLPO) thought to be involved in promoting sleep. Using an acute in vitro preparation of the rat anterior hypothalamus/preoptic area, we found that whereas single-pulse stimulations of the SCN evoked standard fast ionotropic IPSPs and EPSPs, train stimulations unexpectedly evoked a long-lasting inhi- bition (LLI). Such LLIs could also be evoked in VLPO neurons by pressure application of NMDA within the SCN, indicating the specific activation of SCN neurons. This LLI was shown to result from the presynaptic facilitation of noradrenaline release, because it was ␣ suppressed in presence of yohimbine, a selective antagonist of 2-adrenoreceptors. The LLI depended on the opening of a potassium conductance, because it was annulled at EK and could be reversed below EK. These results show that the SCN can provide an LLI of the sleep-promoting VLPO neurons that could play a role in the circadian organization of the sleep–waking cycle. -
Ketamine Dual Therapy Stops Cholinergic Status
FULL-LENGTH ORIGINAL RESEARCH Midazolam–ketamine dual therapy stops cholinergic status epilepticus and reduces Morris water maze deficits *†Jerome Niquet, †Roger Baldwin, †Keith Norman, †Lucie Suchomelova, ‡Lucille Lumley, and *†§Claude G. Wasterlain Epilepsia, **(*):1–10, 2016 doi: 10.1111/epi.13480 SUMMARY Objective: Pharmacoresistance remains an unsolved therapeutic challenge in status epilepticus (SE) and in cholinergic SE induced by nerve agent intoxication. SE triggers a rapid internalization of synaptic c-aminobutyric acid A (GABAA) receptors and externalization of N-methyl-D-aspartate (NMDA) receptors that may explain the loss of potency of standard antiepileptic drugs (AEDs). We hypothesized that a drug com- bination aimed at correcting the consequences of receptor trafficking would reduce SE severity and its long-term consequences. Methods: A severe model of SE was induced in adult Sprague-Dawley rats with a high dose of lithium and pilocarpine. The GABAA receptor agonist midazolam, the NMDA receptor antagonist ketamine, and/or the AED valproate were injected 40 min after SE onset in combination or as monotherapy. Measures of SE severity were the primary outcome. Secondary outcomes were acute neuronal injury, spontaneous recurrent seizures (SRS), and Morris water maze (MWM) deficits. Results: Midazolam–ketamine dual therapy was more efficient than double-dose Jerome Niquet is an midazolam or ketamine monotherapy or than valproate–midazolam or valproate– associate researcher ketamine dual therapy in reducing several parameters of SE severity, suggesting a at the Department of synergistic mechanism. In addition, midazolam–ketamine dual therapy reduced Neurology, David SE-induced acute neuronal injury, epileptogenesis, and MWM deficits. Geffen School of Significance: This study showed that a treatment aimed at correcting maladaptive Medicine at UCLA. -
Retinal Afferents to the Dorsal Raphe Nucleus in Rats and Mongolian Gerbils
THE JOURNAL OF COMPARATIVE NEUROLOGY 414:469–484 (1999) Retinal Afferents to the Dorsal Raphe Nucleus in Rats and Mongolian Gerbils KATHERINE V. FITE,1* SKIRMANTAS JANUSˇ ONIS,1 WARREN FOOTE,2 AND LYNN BENGSTON1 1Neuroscience and Behavior Program, University of Massachusetts, Amherst, Massachusetts 01003 2Massachusetts General Hospital, Boston, Massachusetts 02114 ABSTRACT A direct pathway from the retina to the dorsal raphe nucleus (DRN) has been demonstrated in both albino rats and Mongolian gerbils. Following intraocular injection of cholera toxin subunit B (CTB), a diffuse stream of CTB-positive, fine-caliber optic axons emerged from the optic tract at the level of the pretectum/anterior mesencephalon. In gerbils, CTB-positive axons descended ventromedially into the periaqueductal gray, moving caudally and arborizing extensively throughout the DRN. In rats, the retinal-DRN projection com- prised fewer, but larger caliber, axons, which arborized in a relatively restricted region of the lateral and ventral DRN. Following injection of CTB into the lateral DRN, retrogradely labeled ganglion cells (GCs) were observed in whole-mount retinas of both species. In gerbils, CTB-positive GCs were distributed over the entire retina, and a nearest-neighbor analysis of CTB-positive GCs showed significant regularity (nonrandomness) in their distribution. The overall distribution of gerbil GC soma diameters ranged from 8 to 22 µm and was skewed slightly towards the larger soma diameters. Based on an adaptive mixtures model statistical analysis, two Gaussian distributions appeared to comprise the total GC distribution, with mean soma diameters of 13 (SEM Ϯ1.7) µm, and 17 (SEM Ϯ1.5) µm, respectively. In rats, many fewer CTB-positive GCs were labeled following CTB injections into the lateral DRN, and nearly all occurred in the inferior retina. -
Role of the Suprachiasmatic Nucleus
Brain Research Reviews 49 (2005) 429–454 www.elsevier.com/locate/brainresrev Review Circadian regulation of sleep in mammals: Role of the suprachiasmatic nucleus Ralph E. MistlbergerT Department of Psychology, Simon Fraser University, 8888 University Drive, Burnaby, Canada BC V5A 1S6 Accepted 7 January 2005 Available online 8 March 2005 Abstract Despite significant progress in elucidating the molecular basis for circadian oscillations, the neural mechanisms by which the circadian clock organizes daily rhythms of behavioral state in mammals remain poorly understood. The objective of this review is to critically evaluate a conceptual model that views sleep expression as the outcome of opponent processes—a circadian clock-dependent alerting process that opposes sleep during the daily wake period, and a homeostatic process by which sleep drive builds during waking and is dissipated during sleep after circadian alerting declines. This model is based primarily on the evidence that in a diurnal primate, the squirrel monkey (Saimiri sciureus), ablation of the master circadian clock (the suprachiasmatic nucleus; SCN) induces a significant expansion of total daily sleep duration and a reduction in sleep latency in the dark. According to this model, the circadian clock actively promotes wake but only passively gates sleep; thus, loss of circadian clock alerting by SCN ablation impairs the ability to sustain wakefulness and causes sleep to expand. For comparison, two additional conceptual models are described, one in which the circadian clock actively promotes sleep but not wake, and a third in which the circadian clock actively promotes both sleep and wake, at different circadian phases. Sleep in intact and SCN-damaged rodents and humans is first reviewed, to determine how well the data fit these conceptual models. -
Drugs Affecting the Autonomic Nervous System-3 Cholinergic Antagonists Assistant Prof
Drugs Affecting the Autonomic Nervous System-3 Cholinergic Antagonists Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia The cholinergic antagonists (also called cholinergic blockers, parasympatholytics or anticholinergic drugs) Bind to cholinoceptors, but they do not trigger the usual receptor-mediated intracellular effects. The most useful of these agents selectively block muscarinic synapses of the parasympathetic nerves Cholinergic antagonist classified into: Antimuscarinic Agents: • M1 Selective. • Non selective. Antinicotinic Agents: • Ganglionic Blocking Agents. • Neuromuscular Blocking Agents. Antimuscarinic Agents Tertiary amine (Alkaloid esters of tropic acid) • Atropine: (prototype) • Hemoatropine: • Scopolamine. Quaternary amine (Semi synthetic & synthetic) Produce more peripheral effects with decrease CNS effect. • Propantheline • Ipratropium • Clidinium bromide. Sites of Actions of Cholinergic Antagonists Antimuscarinic Agents Tertiary amine Atropine A tertiary amine belladonna alkaloid Acts both centrally and peripherally It has a high affinity for muscarinic receptors, binds competitively & reversiblely,preventing Ach from binding to that site. Block muscarinic receptors causing inhibition of all muscarinic functions. Block the few exceptional sympathetic neurons that are cholinergic, such as those innervating salivary and sweat glands. Have little or no action at skeletal neuromuscular junctions or autonomic ganglia (because they do not block nicotinic receptors). -
Basal Forebrain Glutamatergic Modulation of Cortical Acetylcholine Release
SYNAPSE 39:201–212 (2001) Basal Forebrain Glutamatergic Modulation of Cortical Acetylcholine Release JIM FADEL, MARTIN SARTER, AND JOHN P. BRUNO* Departments of Psychology and Neuroscience, The Ohio State University, Columbus, Ohio KEY WORDS acetylcholine; basal forebrain; cortex; microdialysis; glutamate recep- tors; kainate; NMDA ABSTRACT The mediation of cortical ACh release by basal forebrain glutamate receptors was studied in awake rats fitted with microdialysis probes in medial prefrontal cortex and ipsilateral basal forebrain. Repeated presentation of a stimulus consisting of exposure to darkness with the opportunity to consume a sweetened cereal resulted in a transient increase in cortical ACh efflux. This stimulated release was dependent on basal forebrain glutamate receptor activity as intrabasalis perfusion with the ionotropic glutamate receptor antagonist kynurenate (1.0 mM) markedly attenuated darkness/ cereal-induced ACh release. Activation of AMPA/kainate receptors by intrabasalis per- fusion of kainate (100 M) was sufficient to increase cortical ACh efflux even under basal (nonstimulated) conditions. This effect of kainate was blocked by coperfusion with the antagonist DNQX (0.1–5.0 mM). Stimulation of NMDA receptors with intrabasalis perfusion of NMDA (50 or 200 M) did not increase basal cortical ACh efflux. However, perfusion of NMDA in rats following exposure to the darkness/cereal stimulus resulted in a potentiation of both the magnitude and duration of stimulated cortical ACh efflux. Moreover, intrabasalis perfusion of the higher dose of NMDA resulted in a rapid increase in cortical ACh efflux even before presentation of the darkness/cereal stimulus, suggesting an anticipatory change in the excitability of basal forebrain cholinergic neurons. These data demonstrate that basal forebrain glutamate receptors contribute to the stimulation of cortical ACh efflux in response to behavioral stimuli.